Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMHL7OB)

• Drug Name: Uracil mustard Drug Info
• Synonyms: Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol
• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 6194
  ChEBI ID: CHEMBL9884
  CAS Number: CAS 66-75-1
  TTD Drug ID: D0J9UN

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Influenza A	2.07	0.00e+0	156/172 (90.7%)	TNFRSF10B;IRF9;MX1;...
p53 signaling pathway	1.99	0.00e+0	63/73 (86.3%)	SESN1;CDKN1A;TP53I3;...
Graft-versus-host disease	1.86	2.35e-2	32/42 (76.19%)	FAS;IL1B;HLA-B;...
Necroptosis	1.86	1.76e-2	113/159 (71.07%)	TNFRSF10B;IRF9;CAPN1;...
Steroid biosynthesis	1.85	1.88e-2	19/20 (95%)	SC5D;TM7SF2;LSS;...
Hepatitis C	1.84	1.56e-2	139/157 (88.54%)	CDKN1A;IRF9;MX1;...
Viral myocarditis	1.81	2.18e-2	53/60 (88.33%)	SGCB;CASP8;ICAM1;...
NOD-like receptor signaling pathway	1.78	2.35e-2	145/181 (80.11%)	IRF9;CXCL8;PYCARD;...
Arrhythmogenic right ventricular cardiomyopathy	1.76	2.87e-2	70/77 (90.91%)	GJA1;ITGB4;SGCB;...
Epstein-Barr virus infection	1.74	3.52e-2	189/202 (93.56%)	CDKN1A;DDB2;IRF9;...
Allograft rejection	1.73	3.94e-2	32/38 (84.21%)	FAS;HLA-B;HLA-F;...
Kaposi sarcoma-associated herpesvirus infection	1.72	3.71e-2	172/193 (89.12%)	CDKN1A;IRF9;CXCL8;...
Pathogenic Escherichia coli infection	1.71	3.88e-2	152/197 (77.16%)	TNFRSF10B;TNFSF10;CXCL8;...
Valine, leucine and isoleucine degradation	1.71	3.69e-2	42/48 (87.5%)	ABAT;ALDH2;DLD;...
RIG-I-like receptor signaling pathway	1.70	4.61e-2	64/70 (91.43%)	CXCL10;ISG15;CXCL8;...
Herpes simplex virus 1 infection	1.69	4.47e-2	165/498 (33.13%)	IRF9;TAP1;OAS1;...
Type I diabetes mellitus	1.69	4.28e-2	38/43 (88.37%)	FAS;IL1B;HLA-B;...
Bacterial invasion of epithelial cells	1.68	4.23e-2	59/77 (76.62%)	CDH1;CTNNB1;MET;...
Measles	1.67	4.63e-2	133/139 (95.68%)	IRF9;MX1;OAS1;...
Thiamine metabolism	-1.70	4.47e-2	12/15 (80%)	ACP1;ALPL;AK4
Metabolism of xenobiotics by cytochrome P450	-1.79	2.13e-2	49/77 (63.64%)	CYP2B6;ADH7;CYP2C9;...
Cysteine and methionine metabolism	-1.79	2.67e-2	43/50 (86%)	SDS;MTAP;MAT1A;...
Ferroptosis	-1.85	7.62e-3	36/41 (87.8%)	GPX4;ACSL1;SLC39A14;...
Progesterone-mediated oocyte maturation	-1.96	0.00e+0	75/100 (75%)	AKT1;CDC23;MAPK8;...
Steroid hormone biosynthesis	-2.02	0.00e+0	43/61 (70.49%)	UGT2A3;AKR1D1;CYP7B1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	12uM - 100uM	48H	Hide ▲

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	12uM - 100uM	48H	Hide ▲